<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672707</url>
  </required_header>
  <id_info>
    <org_study_id>BCYY-BEFA-2020BCCT002</org_study_id>
    <nct_id>NCT04672707</nct_id>
  </id_info>
  <brief_title>Study on the Pharmacokinetics of Bromine Hexane Hydrochloride Tablets in Healthy Adults</brief_title>
  <official_title>Study on the Pharmacokinetics of Bromine Hexane Hydrochloride Tablets in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wanbangde Pharmaceutical Group Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital of Wenzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is about increasing the dosage of bromine hexane hydrochloride to safety&#xD;
      volume and continue to give it frequently in the new crown virus treatment could improve the&#xD;
      efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose is to study the pharmacokinetic characteristics and safety of bromine hexane&#xD;
      hydrochloride in healthy adults after oral administration of bromine hexane hydrochloride&#xD;
      tablets. Then to explore the mechanism related to the role of transmembrane serine proteases&#xD;
      (TMPRSSs) through the study, and to provide the basis for the clinical rational&#xD;
      administration of bromine hexane hydrochloride tablets.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 12, 2021</start_date>
  <completion_date type="Anticipated">December 12, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Maximum observed concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC 0-16h)</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>16 hour dosing period; 3 dosing periods each separated by 2 day washout</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(AUC to infinity)</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>16 hour dosing period; 3 dosing periods each separated by 2 day washout</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC_%Extrap</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>The proportion of the AUC (AUC to infinity) from the last point until we theoretically extrapolate to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration (Tmax)</measure>
    <time_frame>2 to 2.5 hours</time_frame>
    <description>16 hour dosing period; 3 dosing periods each separated by 2 day washout</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance rate（CL）</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Apparent clearance rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>5 hour</time_frame>
    <description>16 hour dosing period; 3 dosing periods each separated by 2 day washout</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Terminal disposition rate constant</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bromhexine Hydrochloride Tablet, 32 mg, 8 mg 4 tablets, three times a day, for 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bromhexine Hydrochloride Tablet, 48 mg, 8 mg 6 tablets, three times a day, continuous service within 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bromhexine Hydrochloride Tablet, 64 mg ,8 mg spec 8 tablets ,3 times daily ,2 days in succession)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bromhexine Hydrochloride Tablets, 80 mg ,8 mg Standard preparation 10 tablets ,3 times a day ,2 day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromhexine Hydrochloride Tablet</intervention_name>
    <description>32 mg</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromhexine Hydrochloride Tablet</intervention_name>
    <description>48 mg</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromhexine Hydrochloride Tablet</intervention_name>
    <description>64 mg</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromhexine Hydrochloride Tablet</intervention_name>
    <description>80mg</description>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult males and non-pregnant non-lactating females aged 18-55 years, including&#xD;
             boundary values, trial period Over 55 years of age);&#xD;
&#xD;
          2. Male body weight ≥50 kg, female body weight ≥45 kg, body mass index (BMI )19,282&#xD;
             Between, including boundary values;&#xD;
&#xD;
          3. Health, no heart, liver, kidney, digestive tract, nervous system, mental disorders and&#xD;
             metabolic disease history;&#xD;
&#xD;
          4. Sign informed consent before the trial, fully understand the content, process and&#xD;
             possible adverse reactions, and communicate well with the researchers.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have participated in any clinical trial within 90 days before the trial or plan to&#xD;
             participate in other clinical trials during the trial;&#xD;
&#xD;
          2. Have undergone major surgery within 90 days before the trial or plan to undergo&#xD;
             surgery within 3 months after the trial;&#xD;
&#xD;
          3. Blood loss or donation of more than 300 blood mL (excluding female physiological blood&#xD;
             loss) within 90 days prior to the trial, or blood transfusion;&#xD;
&#xD;
          4. Suffering from esophageal reflux, gastric bleeding or peptic ulcer disease within 180&#xD;
             days prior to the trial, more than once a week with heartburn, or any surgical&#xD;
             procedure that may affect drug absorption (e.g. cholecystectomy);&#xD;
&#xD;
          5. a person with a specific history of allergies (asthma, urticaria, eczema, etc.), or an&#xD;
             allergic constitution (e.g. allergic to two or more drugs, food or pollen), or a known&#xD;
             component of the drug*or analogues/lactose allergy/intolerance;&#xD;
&#xD;
             *The main components of the test drug: bromine hexane hydrochloride, excipients:&#xD;
             starch, lactose, magnesium stearate.&#xD;
&#xD;
          6. Use of any medication within 28 days prior to the trial, including the use of&#xD;
             prescription, over-the-counter and/or alternative medicines (e.g., medicinal meals,&#xD;
             herbal medicines, hemostatic or health products) and the use of hormonal contraception&#xD;
             or vaccines;&#xD;
&#xD;
          7. History of substance abuse;&#xD;
&#xD;
          8. Urine screening for substance abuse (tetrahydrocannabinol, benzodiazepine,&#xD;
             barbiturates, morphine, cocaine, methamphetamine) was positive;&#xD;
&#xD;
          9. More than 3 cigarettes per day during the 90 days before the test; Alcoholism, Over 7&#xD;
             drinks per week for women and over 14 drinks per week for men (1=150 mL wine =360 mL&#xD;
             beer and 45 spirits);&#xD;
&#xD;
         10. Positive breath test;&#xD;
&#xD;
         11. The body temperature (ear temperature)≥37.5℃, the respiration was obviously abnormal,&#xD;
             and the researchers thought it was not suitable to take part in the experiment. The&#xD;
             systolic blood pressure &gt;140 mmHg or &lt;90 mmHg, diastolic blood pressure (diastolic&#xD;
             blood pressure) was 90 mmHg or 60 times 100/min or &gt;;&#xD;
&#xD;
         12. Positive human immunodeficiency virus antibody (HIV-Ab), hepatitis B virus surface&#xD;
             antigen (HBsAg), hepatitis C virus antibody (HCV-Ab) or Treponema pallidum specific&#xD;
             antibody (TPHA);&#xD;
&#xD;
         13. There are special requirements for diet, during the test can not comply with a unified&#xD;
             diet;&#xD;
&#xD;
         14. Subjects refused to comply with the 48-hour ban on caffeine, alcohol, grapefruit and&#xD;
             food (including tea, chocolate, coffee, cola, etc.);&#xD;
&#xD;
         15. Participants with partners refused to use effective contraception within 180 days from&#xD;
             screening to completion of the trial；&#xD;
&#xD;
         16. Female subjects were positive for blood/urine pregnancy;&#xD;
&#xD;
         17. (c) Persons with renal insufficiency, impairment or previous urinary system disease;&#xD;
&#xD;
         18. hereditary galactose intolerance, lactase deficiency, or glucose-galactose&#xD;
             malabsorption;&#xD;
&#xD;
         19. Halo acupuncture, halo blood and venous blood collection difficulties;&#xD;
&#xD;
         20. The physical examination has an obvious abnormality, and the researcher thinks it is&#xD;
             not suitable to participate in the experiment;&#xD;
&#xD;
         21. Electrocardiogram examination has an obvious abnormality, and the researcher thinks it&#xD;
             is not suitable to participate in the experiment;&#xD;
&#xD;
         22. Blood biochemistry, blood routine, urine routine examination have obvious abnormal,&#xD;
             and the researchers think it is not suitable to participate in the test;&#xD;
&#xD;
         23. The subjects may not be able to complete the study for other reasons or may not be&#xD;
             suitable for participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ting Li, PHD</last_name>
    <phone>0577-88002664</phone>
    <email>liting1021@aliyun.com</email>
  </overall_contact>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 13, 2020</study_first_submitted>
  <study_first_submitted_qc>December 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromhexine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

